Stenoparib

N/A

Report date: 2026/04/08 16:01:35
NME

Base Information

Drug NameStenoparib
Drug Alias NameStenoparib - Allarity Therapeutics2X-121/PARPiE-7449MGI-250362X-121
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsTankyrase inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors +[4] 
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1Tankyrase
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOncoheroes Biosciences IncAllarity Therapeutics A/S
Inactive CompaniesUT Health San AntonioEisai Ltd
Active IndicationsMetastatic breast cancerOvarian Neoplasms
Inactive IndicationsSolid tumoursTriple Negative Breast NeoplasmsBreast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A